



specification inserting SEQ ID NOS had not been entered in the Amendment mailed July 11, 2001, Applicants have provided the amended full paragraphs that include the SEQ ID NOS. A substitute sequence listing along with a Computer Readable Form of the Sequence Listing is provided to incorporate all of the sequences disclosed in the application. The type of artificial sequence has been amended to recite a portion of the epitope in the first instance and synthetic peptides in the other instances. The undersigned hereby states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR 1.821 are identical. No new matter has been added by this amendment. Favorable consideration of this application is respectfully requested. A version to show changes made accompanies this amendment.

Respectfully submitted,

  
Myra H. McCormack, Ph.D.  
Attorney for Applicants  
Reg. No. 36,602

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-6932  
Dated: January 16, 2002



ORT-1199

COPY OF PAPERS  
ORIGINALLY FILED

1

VERSION TO SHOW CHANGES MADE

#### IN THE SPECIFICATION

The first paragraph to show a chain of priority has been added.

At page 5, line 1, paragraph 1 has been amended to read:

-- The hybridoma cell lines designated 37B1 and 8G6 were deposited on December 11, 1997 and March 4, 1999 respectively pursuant to, and in satisfaction of, the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Virginia 2010-220009 under ATCC Accession Nos. HB-12441 and HB-12657, respectively.--

At page 7, line 2 the paragraph has been amended as follows:

-- Such first antibodies include, but are not limited to, the monoclonal antibodies produced by the hybridoma cell lines 37B1 (ATCC Accession No. HB-12441) and 8G6 (ATCC Accession No. HB-12657). Conditions which permit these antibodies to bind to but not activate CD8<sup>+</sup> cells are well known in the art. These conditions [are described] include, for example, a suitable buffer such as Ca<sup>2+</sup> and Mg<sup>2+</sup>-free Dulbecco's Phosphate Buffer Saline (DPBS) containing 1% Human serum Albumin (HAS) and 0.2% sodium citrate and gentle mixing by "end over end" rotation on a rotator set at 4 rpm.--

A number of sequence numbers have been added to the specification.

#### IN THE CLAIMS

Claims 7, 9 and 13 have been canceled and claim 16 has been added.

The following claims have been amended as follows:

COPY of B

- N.E.
1. (Twice Amended) A method of isolating human CD8+ cells which comprises the steps of
    - (a) contacting a sample of isolated peripheral mononuclear blood cells with a first antibody which specifically binds to the sequence AAEGLDLTQRFSG (SEQ ID NO:1) or portion thereof, on CD8 molecules present on the surface of human CD8+ cells but does not activate the CD8+ cells once bound thereto, under conditions permitting the formation of a first complex between the CD8+ cell and first antibody;
    - (b) separating from the sample any first antibody not present in the resulting first complex;
    - (c) contacting the sample with a second, immobilized antibody which specifically binds to the first antibody in the first complex, under conditions permitting the formation of an immobilized second complex between the first complex and the second antibody, thereby immobilizing the CD8+ cells present in the sample;
    - (d) separating from the resulting immobilized second complex the cells present in the sample which were not immobilized in step (c);
    - (e) contacting the immobilized second complex under suitable conditions with an agent which causes the dissociation of the second complex into CD8+ cells and an immobilized third complex between the first antibody and second antibody; and

(f) separating the immobilized third complex from the CD8+ cells, thereby isolating the CD8+ cells.

- NE
8. (Amended) The hybridoma cell lines [of claim 7, wherein the hybridoma cell line is selected from the group consisting of the cell line] designated 37B1 (ATCC Accession No. HB-12441) and [the cell line designated] 8G6 (ATCC Accession No. HB-12657).

- NE.
11. (Twice Amended) A polypeptide useful for generating the monoclonal antibody of claim 9 consisting essentially [of which comprises] the amino acid sequence AAEGLDTQRFSG (SEQ ID NO:1).

- NE.
12. (Twice Amended) The polypeptide of claim 11 wherein the polypeptide [is the polypeptide designated CD8-3 and having] consists of the amino acid sequence AAEGLDTQRFSG (SEQ ID NO:[1]2).